NEW YORK, June 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=85496&from=4CLASS PERIOD: February 3, 2022 to February 13, 20 ...

The healthcare sector will be one area of secular growth over the next decade. Several demand drivers will benefit the best healthcare stocks to buy across the entire value chain.First, let’s highlight the major healthcare tailwinds starting with an aging population. The baby boomer generation (20% of the U.S. population) is transitioning into older age. This shift will create a surging demand for healthcare services and products such as insurance, pharmaceuticals, medical devices and hospitals.Indeed, esti ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Colorado on behalf of those who acquired Biogen, Inc (“Biogen” or the “Company”) (NASDAQ: BIIB) securities during the period of February 3, 2022 through February 13, 2024, inclusive (“the Class Period”). Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click here t ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and F ...

Biogen Inc. (NASDAQ:BIIB) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:40 AM ET Company Participants Alisha Alaimo - Head and President of North-America Chuck Triano - Head of IR Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone. Thank you so much for joining us. Really pleased to have the Biogen team here with us. We have Alisha Alaimo who's the President, Head of North America; and Chuck Triano, Head of IR. With that, let ...

Biogen Inc. Conference Call Summary Company Overview - **Company**: Biogen Inc. (NASDAQ:BIIB) - **Event**: Goldman Sachs 45th Annual Global Healthcare Conference - **Date**: June 12, 2024 Key Industry Insights - **Focus on Alzheimer's Treatment**: Biogen is actively involved in the Alzheimer's treatment space, particularly with the launch of LEQEMBI, a monoclonal antibody aimed at slowing the decline of Alzheimer's disease [7][8][9]. - **Market Dynamics**: The entry of competitors, such as Lilly, is viewed positively as it is expected to accelerate market development for Alzheimer's treatments [12][13][14]. Core Company Strategies - **Return to Growth**: Biogen has undergone a transformation focusing on stabilizing and then thriving, following challenges with ADUHELM. The company is now emphasizing financial discipline and capital allocation [4][5]. - **Reengineering Efforts**: The organization has been restructured to optimize capital allocation and enhance long-term shareholder value [5][56]. Product Launch Updates - **LEQEMBI Launch**: - The launch has seen an acceleration in patient uptake, particularly noted in March, with a significant increase in healthcare providers (HCPs) prescribing the drug [10][11][22]. - The company is focusing on expanding the number of HCPs and sites ordering LEQEMBI, with a notable increase in the number of physicians treating patients [19][20][22]. - The company is also expanding its U.S. sales force by 30% to support the launch [25][26]. - **SKYCLARYS for Friedreich's Ataxia**: - The product has penetrated 24% of the market with over 1,100 patients on the drug. The focus is now on identifying patients outside of centers of excellence [36][37]. - The company is employing sophisticated models to locate patients with general ataxia who may have Friedreich's ataxia [39]. - **ZURZUVAE Launch**: - The launch has exceeded internal expectations, with OB/GYNs emerging as the primary prescribers, contrary to initial assumptions that psychiatrists would dominate [51][52]. Financial Outlook - **Margin Improvement**: Biogen aims to optimize capital allocation to enhance margins, which are currently below peer averages. The company is focused on revenue growth that translates efficiently to the bottom line [55][56]. - **Future Growth Potential**: The leadership team is committed to a return to growth, leveraging strong science and regulatory capabilities alongside improved financial management [56][57]. Regulatory and Market Considerations - **Regulatory Filings**: The IV maintenance filing for LEQEMBI has a PDUFA date set for January 25, 2025, with additional subcutaneous formulations in the pipeline [29][30]. - **Medicare Part D Dynamics**: The redesign of Medicare Part D is expected to impact pricing and coverage, but the full effects will not be known until the subcutaneous formulation is on the market [32][33][34]. Conclusion - Biogen is strategically positioned to enhance its market presence in the Alzheimer's treatment space and rare diseases through focused product launches and a commitment to financial discipline. The company is optimistic about its growth trajectory and the potential for improved margins in the coming years.

PALM BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than doubled. In 2000, it was estimated by the National Multiple Sclerosis Society that around 400,000 Americans had the disease. In 2017, that estimate had jumped to 900,000. Although estimates between studies differ, it's commonly accepted that about 800,000-900,000 individuals in the United States suffer from MS, out ...

NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and F ...

LOS ANGELES, June 10, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB).Class Period: February 3, 2022 – February 13, 2024Lead Plaintiff Deadline: July 22, 2024If you are a shareholder who suffered a loss, click here to participate.The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to i ...

Biogen (BIIB) and Japanese partner Eisai announced that the FDA has accepted Eisai’s supplemental biologics license application (sBLA) seeking approval for a maintenance intravenous (“IV”) dosing version of Leqembi for the treatment of early Alzheimer’s disease. The FDA is expected to give its decision on the sBLA on Jan 25, 2025.Leqembi was approved as an injection for intravenous use by the FDA for early Alzheimer’s disease in the United States in July 2023. Leqembi is also approved in China and Japan. Re ...